Your browser is no longer supported. Please, upgrade your browser.
CASI CASI Pharmaceuticals, Inc. daily Stock Chart
CASI Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own3.90% Shs Outstand100.92M Perf Week-9.34%
Market Cap206.99M Forward P/E- EPS next Y-0.20 Insider Trans- Shs Float70.96M Perf Month1.85%
Income-39.70M PEG- EPS next Q-0.06 Inst Own18.70% Short Float2.19% Perf Quarter-26.01%
Sales10.20M P/S20.29 EPS this Y-48.00% Inst Trans0.09% Short Ratio3.14 Perf Half Y-3.51%
Book/sh0.63 P/B2.62 EPS next Y20.00% ROA-39.40% Target Price- Perf Year-49.70%
Cash/sh0.37 P/C4.52 EPS next 5Y- ROE-55.30% 52W Range1.15 - 3.67 Perf YTD-46.60%
Dividend- P/FCF- EPS past 5Y12.10% ROI-64.30% 52W High-55.04% Beta0.65
Dividend %- Quick Ratio13.20 Sales past 5Y180.60% Gross Margin5.30% 52W Low43.48% ATR0.08
Employees125 Current Ratio13.30 Sales Q/Q- Oper. Margin- RSI (14)47.13 Volatility3.53% 4.94%
OptionableNo Debt/Eq0.00 EPS Q/Q46.10% Profit Margin- Rel Volume0.13 Prev Close1.65
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume494.71K Price1.65
Recom- SMA201.73% SMA50-3.22% SMA200-21.86% Volume64,067 Change0.00%
Sep-22-16Initiated Maxim Group Buy $4
Oct-29-15Resumed H.C. Wainwright Buy $2.50 → $3
Jun-23-15Initiated H.C. Wainwright Buy $2.50
Oct-02-20 07:00AM  
Sep-29-20 07:00AM  
Sep-11-20 07:00AM  
Sep-07-20 08:28AM  
Aug-26-20 05:31AM  
Aug-11-20 11:30AM  
Aug-10-20 07:29AM  
Jul-22-20 09:05AM  
Jul-21-20 04:01PM  
Jul-09-20 09:39AM  
Jun-08-20 07:00AM  
Jun-02-20 07:00AM  
May-31-20 05:38PM  
May-25-20 06:14AM  
May-14-20 06:47AM  
May-12-20 06:43AM  
May-11-20 07:00AM  
May-08-20 09:05AM  
Apr-07-20 07:00AM  
Mar-31-20 07:05AM  
Mar-29-20 08:08AM  
Mar-16-20 07:00AM  
Mar-02-20 06:03AM  
Feb-21-20 07:46AM  
Feb-07-20 10:49AM  
Feb-04-20 07:51AM  
Jan-26-20 08:33AM  
Dec-20-19 05:27AM  
Dec-03-19 09:00PM  
Nov-14-19 05:17AM  
Nov-12-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 09:33AM  
Sep-19-19 07:00AM  
Sep-16-19 06:00AM  
Sep-03-19 07:00AM  
Aug-20-19 07:15PM  
Aug-19-19 12:22PM  
Aug-16-19 10:20AM  
Aug-15-19 07:15PM  
Aug-12-19 03:03PM  
Aug-09-19 07:00AM  
Jul-31-19 10:44AM  
Jun-17-19 07:00AM  
Jun-03-19 07:00AM  
May-20-19 09:45AM  
May-15-19 07:00AM  
May-13-19 10:00AM  
May-03-19 08:42AM  
Apr-18-19 04:15PM  
Apr-17-19 07:00AM  
Apr-02-19 07:00AM  
Mar-29-19 07:00AM  
Mar-13-19 07:00AM  
Mar-07-19 07:00AM  
Feb-26-19 08:14AM  
Feb-20-19 08:15AM  
Feb-19-19 07:00AM  
Feb-06-19 07:00AM  
Dec-28-18 11:45AM  
Dec-26-18 09:32AM  
Dec-03-18 09:15AM  
Nov-30-18 04:05PM  
Nov-28-18 08:40AM  
Nov-16-18 07:00AM  
Nov-14-18 07:00AM  
Oct-24-18 08:00AM  
Oct-23-18 03:47PM  
Oct-18-18 08:40AM  
Oct-02-18 07:00AM  
Sep-28-18 07:00AM  
Sep-14-18 07:00AM  
Aug-27-18 08:20AM  
Aug-14-18 07:00AM  
Jul-05-18 07:43AM  
Jul-03-18 01:05PM  
Jun-25-18 08:00AM  
Jun-21-18 04:14PM  
May-31-18 08:30AM  
May-29-18 07:00AM  
May-15-18 07:00AM  
May-07-18 07:30AM  
May-02-18 12:01PM  
Apr-30-18 04:47PM  
Apr-16-18 07:40AM  
Apr-08-18 07:17AM  
Apr-06-18 04:23PM  
Apr-05-18 08:00AM  
Apr-03-18 07:00AM  
Mar-29-18 07:00AM  
Mar-21-18 08:10AM  
Mar-20-18 09:29AM  
Mar-05-18 08:30AM  
Feb-09-18 07:00AM  
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang LarryPresidentJul 22Buy1.9020,15338,29120,153Jul 24 04:05 PM
He Wei-WuChairman and CEOJul 22Buy1.901,200,0002,280,0007,532,347Jul 24 04:03 PM
He Wei-WuChairman and CEOJul 22Buy1.902,952,4265,609,6094,836,523Jul 24 04:03 PM
He Wei-WuChairman and CEOMay 20Buy2.3756,464133,8201,884,097May 21 05:01 PM
He Wei-WuChairman and CEOMay 19Buy2.0329,80160,4961,827,663May 21 05:01 PM
He Wei-WuChairman and CEOMay 18Buy2.02338,932684,6431,797,832May 19 05:55 PM
He Wei-WuChairman and CEOMay 15Buy1.82100,000182,0001,458,900May 19 05:55 PM
He Wei-WuChairman and CEOMar 27Buy2.086,88014,3101,358,900Mar 30 04:01 PM
He Wei-WuChairman and CEOMar 26Buy2.09328,095685,7191,352,020Mar 27 05:07 PM
He Wei-WuChairman and CEOMar 25Buy1.94196,398381,0121,023,925Mar 27 05:07 PM
He Wei-WuChairman and CEOMar 19Buy1.57234,488368,1466,332,347Mar 19 05:39 PM
He Wei-WuChairman and CEOMar 18Buy1.52501,322762,0096,097,859Mar 19 05:39 PM
He Wei-WuChairman and CEOMar 17Buy1.50264,192396,2885,596,537Mar 19 05:39 PM